MediciNova reports mixed signals from MN-001 clinical trial
The Phase 2 study missed its primary endpoints, while several lipid measures improved; the company is reviewing the full dataset.
Makkler Newsroom · Oct 12, 01:07 PM · 1 min read
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Profitability and valuation from the filed statements
Answers from price, statements, peer and news data. Not investment advice.
MakklerAI Q&A is open to MakklerPRO members. Upgrade to MakklerPRO